|
2024
|
Invention
|
Crystalline forms of c21h22cl2n4o2.
The present invention provides crystalline forms of a compou... |
|
|
Invention
|
Deuterated analogs of pyrole inhibitors of erk, synthesis thereof and intermediates thereto.
The... |
|
|
Invention
|
Cancer treatments using combinations of cdk and erk inhibitors.
The present invention provides, ... |
|
2023
|
G/S
|
Scientific research in the fields of oncology,
immuno-oncology, disease, and treatment of diseas... |
|
|
G/S
|
Scientific research in the fields of oncology, immuno-oncology, disease, and treatment of disease... |
|
|
Invention
|
Cancer treatments using combinations of cdk and erk inhibitors. The present invention provides, i... |
|
|
Invention
|
Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto. The... |
|
|
Invention
|
Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto. int... |
|
2022
|
Invention
|
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors.
Polypeptides and proteins tha... |
|
|
Invention
|
C. novyi for the treatment of solid tumors in humans.
The present invention provides, inter alia... |
|
|
Invention
|
2. The present invention provides crystalline forms of a compound of formula (I):
Also provided... |
|
2021
|
Invention
|
Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers.
The pres... |
|
2020
|
Invention
|
2. The present invention provides crystalline forms of a compound of formula (I):
Also provi... |
|
|
Invention
|
Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment. The present invent... |
|
|
Invention
|
C. novyi for the treatment of solid tumors in humans. C. novyi NT, CFUs, and kits for treating or... |
|
|
Invention
|
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors. Polypeptides and proteins that... |
|
|
Invention
|
Anti-cd276 antibodies (b7h3). Polypeptides and proteins that specifically bind to and immunologic... |
|
2018
|
Invention
|
Compositions and methods for treating cancer with atypical braf mutations.
The present invention... |
|
|
Invention
|
Compositions and methods for treating cancer with atypical braf mutations. The present invention ... |
|
2017
|
Invention
|
Tem8 antibodies and their use in treatment and detection of tumors. Antibodies that specifically ... |
|
|
Invention
|
Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers. The prese... |
|
|
Invention
|
2 malonate. The present invention provides a malonate salt of a compound of formula (I):
which ... |
|
|
Invention
|
2 . The present invention provides crystalline forms of a compound of formula (I):
Also prov... |
|
2015
|
Invention
|
Combination therapies using platinum agents and agents that target tumor-associated stroma or tum... |
|
|
Invention
|
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules. The pres... |
|
|
Invention
|
Combination therapies targeting tumor-associated stroma or tumor cells. The present invention pro... |
|
|
Invention
|
Tem8 antibodies and methods of use.
The present invention provides, inter alia, isolated monoclo... |
|
|
Invention
|
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tu... |
|
|
Invention
|
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylat... |
|
|
Invention
|
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase. The pre... |
|
|
Invention
|
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor v... |
|
|
Invention
|
Combination therapies using agents that target tumor-associated stroma or tumor cells and other p... |
|
|
Invention
|
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti... |
|
2014
|
Invention
|
Cancer treatments using combinations of type 2 mek and erk inhibitors. The present invention prov... |
|
|
Invention
|
Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors. The present inventio... |
|
|
Invention
|
Cancer treatment using combinations of erk and raf inhibitors. The present invention provides, in... |
